Diana Mikiewicz
Diana Mikiewicz has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Natalia Łukasiewicz
Institute of Biotechnology and Antibiotics, Starościńska 5, 02-516 Warsaw, Poland
6 shared publications Andrzej Płucienniczak
Institute of Biotechnology and Antibiotics, Starościńska 5, Warszawa, 02-516, Poland
4 shared publications- Anna Bierczynska-Krzysik
Research Network ŁUKASIEWICZ - Institute of Biotechnology and Antibiotics, Staroscinska 5, 02-516, Warsaw, Poland
4 shared publications - Iwona Sokołowska
ŁUKASIEWICZ Research Network-Institute of Biotechnology and Antibiotics, Warsaw, Poland
4 shared publications - Marcin Zieliński
Nomaten, National Centre for Nuclear Research, 05-400 Otwock, Poland
4 shared publications Piotr Borowicz
Institute of Biotechnology and Antibiotics, Starościńska 5, 02-516 Warsaw, Poland
4 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Termedia Sp. z.o.o. in BioTechnologia
- Vol. 106 (4) , 395-408
Gene expression, purification, and functional characterization of recombinant conotoxin μ-TIIIA and TIIIAlaMut in Escherichia coli with clinical evaluation of antiwrinkle efficacy
Background: Conotoxins are small peptides known for their potent and selective activity on ion channels, offering potential applications in both medicine and cosmetology. This study aimed to design and validate recombinant conotoxins (TIIIA and its mutant TIIIAlaMut), assess their biological activity on Nav1.4 sodium channels, and evaluate the anti-wrinkle efficacy of a topical cream containing the recombinant peptide in a group of volunteers. Material and methods: Fusion genes encoding TRX::TIIIA and TRX::TIIIAlaMut were cloned into the pDM vector and expressed in Escherichia coli S4B cells. The proteins were purified using Ni-NTA chromatography, cleaved with CNBr under optimized acidic conditions, and analyzed. Biological activity was tested using patch-clamp electrophysiology in Xenopus laevis oocytes expressing Nav1.4 channels. Additionally, the conotoxin-containing cream was applied by 55 human volunteers in an application study assessing anti-aging effects. Results: Both recombinant peptides were expressed, purified, and activated. Electrophysiological measurements demonstrated their ability to modulate Nav1.4 channel activity, including the version extracted from the cream. In the human study, 47% of participants reported visible reduction of wrinkles. Additional benefits included skin tone evening, erythema reduction, and balanced sebum production in oily skin types. Conclusions: This study describes the design, bacterial expression, and functional analysis of recombinant conotoxins TIIIA and TIIIAlaMut. Their bioactivity was confirmed on Xenopus laevis oocytes expressing human Nav 1.4 channels. The recombinant toxins, including one extracted from a cream, showed effects comparable to a synthetic standard. Application tests demonstrated the conotoxin’s potential in cosmeceuticals, especially in reducing periocular wrinkles and improving skin texture and tone.
- 23 December 2025
- Published by Termedia Sp. z.o.o. in BioTechnologia
- Vol. 106 (4) , 395-408
Open AccessGene expression, purification, and functional characterization of recombinant conotoxin μ-TIIIA and TIIIAlaMut in Escherichia coli with clinical evaluation of antiwrinkle efficacy
Background: Conotoxins are small peptides known for their potent and selective activity on ion channels, offering potential applications in both medicine and cosmetology. This study aimed to design and validate recombinant conotoxins (TIIIA and its mutant TIIIAlaMut), assess their biological activity on Nav1.4 sodium channels, and evaluate the anti-wrinkle efficacy of a topical cream containing the recombinant peptide in a group of volunteers. Material and methods: Fusion genes encoding TRX::TIIIA and TRX::TIIIAlaMut were cloned into the pDM vector and expressed in Escherichia coli S4B cells. The proteins were purified using Ni-NTA chromatography, cleaved with CNBr under optimized acidic conditions, and analyzed. Biological activity was tested using patch-clamp electrophysiology in Xenopus laevis oocytes expressing Nav1.4 channels. Additionally, the conotoxin-containing cream was applied by 55 human volunteers in an application study assessing anti-aging effects. Results: Both recombinant peptides were expressed, purified, and activated. Electrophysiological measurements demonstrated their ability to modulate Nav1.4 channel activity, including the version extracted from the cream. In the human study, 47% of participants reported visible reduction of wrinkles. Additional benefits included skin tone evening, erythema reduction, and balanced sebum production in oily skin types. Conclusions: This study describes the design, bacterial expression, and functional analysis of recombinant conotoxins TIIIA and TIIIAlaMut. Their bioactivity was confirmed on Xenopus laevis oocytes expressing human Nav 1.4 channels. The recombinant toxins, including one extracted from a cream, showed effects comparable to a synthetic standard. Application tests demonstrated the conotoxin’s potential in cosmeceuticals, especially in reducing periocular wrinkles and improving skin texture and tone.
- Open Access
- 1 June 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 170, 105594
Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment
- 1 June 2020
- Published by Elsevier in Protein Expression and Purification
- Vol. 170, 105594
Open AccessBacterial expression and characterization of an anti-CD22 single-chain antibody fragment
- Open Access
- 26 July 2019
- Published by Springer Nature in Molecular Biotechnology
- Vol. 61 (10) , 763-773
Novel Expression Vectors Based on the pIGDM1 Plasmid
Escherichia coli is one of the most widely used hosts for the production of heterologous proteins. Within this host, the choice of cloning vector constitutes a key factor for a satisfactory amplified expression of a target gene. We aimed to develop novel, unpatented expression vectors that enable the stable maintenance and efficient overproduction of proteins in E. coli. A series of expression vectors based on the ColE1-like pIGDM1 plasmid were constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry various antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives contain the inducible T7 promoter while the third one bears the constitutive pms promoter from a clinical strain of Klebsiella pneumoniae. The pIGDM1-derivatives are compatible with other ColE1-like plasmids commonly used in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors contain genes encoding AGA and AGG tRNAs, which supplement the shortage of these tRNAs, increasing the efficiency of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with significantly improved features, including compatibility with vast majority of other plasmids, were designed and constructed. They enable a high-level expression of a desired recombinant gene and therefore constitute a potential, valuable tool for pharmaceutical companies and research laboratories for their own research or for the production of recombinant biopharmaceuticals.
- 26 July 2019
- Published by Springer Nature in Molecular Biotechnology
- Vol. 61 (10) , 763-773
Open AccessNovel Expression Vectors Based on the pIGDM1 Plasmid
Escherichia coli is one of the most widely used hosts for the production of heterologous proteins. Within this host, the choice of cloning vector constitutes a key factor for a satisfactory amplified expression of a target gene. We aimed to develop novel, unpatented expression vectors that enable the stable maintenance and efficient overproduction of proteins in E. coli. A series of expression vectors based on the ColE1-like pIGDM1 plasmid were constructed. The vectors named pIGDMCT7RS, pIGDM4RS and pIGDMKAN carry various antibiotic resistance genes: chloramphenicol, ampicillin or kanamycin, respectively. Two derivatives contain the inducible T7 promoter while the third one bears the constitutive pms promoter from a clinical strain of Klebsiella pneumoniae. The pIGDM1-derivatives are compatible with other ColE1-like plasmids commonly used in molecular cloning. The pIGDMCT7RS and pIGDM4RS vectors contain genes encoding AGA and AGG tRNAs, which supplement the shortage of these tRNAs, increasing the efficiency of synthesis of heterologous proteins. In conclusion, pIGDMCT7RS, pIGDM4RS and pIGDMKAN vectors, with significantly improved features, including compatibility with vast majority of other plasmids, were designed and constructed. They enable a high-level expression of a desired recombinant gene and therefore constitute a potential, valuable tool for pharmaceutical companies and research laboratories for their own research or for the production of recombinant biopharmaceuticals.
- Open Access
- 1 May 2019
- Published by Elsevier in Protein Expression and Purification
- Vol. 157, 63-69
Expression and purification of recombinant human insulin from E. coli 20 strain
- 1 May 2019
- Published by Elsevier in Protein Expression and Purification
- Vol. 157, 63-69
Open AccessExpression and purification of recombinant human insulin from E. coli 20 strain
- Open Access
- 15 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0172600
Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties – From an efficient E. coli expression system to a pharmaceutical formulation
The discovery of insulin led to a revolution in diabetes management. Since then, many improvements have been introduced to insulin preparations. The availability of molecular genetic techniques has enabled the creation of insulin analogs by changing the structure of the native protein in order to improve the therapeutic properties. A new expression vector pIBAINS for production of four recombinant human insulin (INS) analogs (GKR, GEKR, AKR, SR) was constructed and overexpressed in the new E. coli 20 strain as a fusion protein with modified human superoxide dismutase (SOD). The SOD gene was used as a signal peptide to enhance the expression of insulin. SOD::INS was manufactured in the form of insoluble inclusion bodies. After cleavage of the fusion protein with trypsin, the released insulin analogs were refolded and purified by reverse-phase high performance liquid chromatography (RP-HPLC). Elongation of chain A, described here for the first time, considerably improved the stability of the selected analogs. Their identity was confirmed with mass spectrometric techniques. The biological activity of the insulin derivatives was tested on rats with experimental diabetes. The obtained results proved that the new analogs described in this paper have the potential to generate prolonged hypoglycemic activity and may allow for even less frequent subcutaneous administration than once-a-day. When applied, all the analogs demonstrate a rapid onset of action. Such a combination renders the proposed biosynthetic insulin unique among already known related formulations.
- 15 March 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0172600
Open AccessSoluble insulin analogs combining rapid- and long-acting hypoglycemic properties – From an efficient E. coli expression system to a pharmaceutical formulation
The discovery of insulin led to a revolution in diabetes management. Since then, many improvements have been introduced to insulin preparations. The availability of molecular genetic techniques has enabled the creation of insulin analogs by changing the structure of the native protein in order to improve the therapeutic properties. A new expression vector pIBAINS for production of four recombinant human insulin (INS) analogs (GKR, GEKR, AKR, SR) was constructed and overexpressed in the new E. coli 20 strain as a fusion protein with modified human superoxide dismutase (SOD). The SOD gene was used as a signal peptide to enhance the expression of insulin. SOD::INS was manufactured in the form of insoluble inclusion bodies. After cleavage of the fusion protein with trypsin, the released insulin analogs were refolded and purified by reverse-phase high performance liquid chromatography (RP-HPLC). Elongation of chain A, described here for the first time, considerably improved the stability of the selected analogs. Their identity was confirmed with mass spectrometric techniques. The biological activity of the insulin derivatives was tested on rats with experimental diabetes. The obtained results proved that the new analogs described in this paper have the potential to generate prolonged hypoglycemic activity and may allow for even less frequent subcutaneous administration than once-a-day. When applied, all the analogs demonstrate a rapid onset of action. Such a combination renders the proposed biosynthetic insulin unique among already known related formulations.
- 1 March 2016
- Published by Elsevier in Protein Expression and Purification
- Vol. 119, 102-109
Expression of recombinant human bifunctional peptidylglycine α-amidating monooxygenase in CHO cells and its use for insulin analogue modification
- 1 March 2016
- Published by Elsevier in Protein Expression and Purification
- Vol. 119, 102-109
Expression of recombinant human bifunctional peptidylglycine α-amidating monooxygenase in CHO cells and its use for insulin analogue modification
- Open Access
- 27 August 2014
- Published by Springer Nature in Microbial Cell Factories
- Vol. 13 (1) , 1-12
Use of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli
Numerous bacterial human growth hormone (hGH) expression methods under conventional fermentation and induction conditions have been described. Despite significant progress made in this area over the past several years, production of recombinant hGH by using cellular expression systems still requires further optimization. Fusion of the ubiquitin (Ub) tag to the hGH protein allowed to increase of the overall efficiency of the biosynthesis and improve the protein stability. Ub is a protein composed of 76 amino acid residues with a molecular mass of 8.6 kDa, expressed in all eukaryotes. This protein is an element of the universal protein modification system, which does not occur in bacteria, and is a useful carrier for heterologous proteins obtained through expression in Escherichia coli. Purification of Ub-fusion proteins is easier than that of unconjugated recombinant proteins, and Ub can be removed by deubiquitinating proteases (DUBs or UBPs). In the present study the UBPD2C protease, a stable UBP1 analog, was produced as a recombinant protein in E. coli and used for production of recombinant human growth hormone (rhGH). hGH was expressed as a fusion protein with Ub as a tag. Our findings show that the UBPD2C protease is very effective in removing the Ub moiety from recombinant Ub-fused hGH. The described approach enables obtaining a considerable yield of rhGH in a purity required for pharmaceutical products.
- 27 August 2014
- Published by Springer Nature in Microbial Cell Factories
- Vol. 13 (1) , 1-12
Open AccessUse of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli
Numerous bacterial human growth hormone (hGH) expression methods under conventional fermentation and induction conditions have been described. Despite significant progress made in this area over the past several years, production of recombinant hGH by using cellular expression systems still requires further optimization. Fusion of the ubiquitin (Ub) tag to the hGH protein allowed to increase of the overall efficiency of the biosynthesis and improve the protein stability. Ub is a protein composed of 76 amino acid residues with a molecular mass of 8.6 kDa, expressed in all eukaryotes. This protein is an element of the universal protein modification system, which does not occur in bacteria, and is a useful carrier for heterologous proteins obtained through expression in Escherichia coli. Purification of Ub-fusion proteins is easier than that of unconjugated recombinant proteins, and Ub can be removed by deubiquitinating proteases (DUBs or UBPs). In the present study the UBPD2C protease, a stable UBP1 analog, was produced as a recombinant protein in E. coli and used for production of recombinant human growth hormone (rhGH). hGH was expressed as a fusion protein with Ub as a tag. Our findings show that the UBPD2C protease is very effective in removing the Ub moiety from recombinant Ub-fused hGH. The described approach enables obtaining a considerable yield of rhGH in a purity required for pharmaceutical products.
- 13 February 2013
- Published by Springer Nature in Journal of Biomolecular NMR
- Vol. 55 (3) , 303-309
Biosynthetic engineered B28K–B29P human insulin monomer structure in water and in water/acetonitrile solutions
- 13 February 2013
- Published by Springer Nature in Journal of Biomolecular NMR
- Vol. 55 (3) , 303-309
Biosynthetic engineered B28K–B29P human insulin monomer structure in water and in water/acetonitrile solutions
- Open Access
- 1 January 2012
- Published by Springer Nature in Microbial Cell Factories
- Vol. 11 (1) , 109
A novel system for stable, high-level expression from the T7 promoter
The most widespread, efficient prokaryotic protein-producing system is one where the T7 phage polymerase recognizes the T7 phage promoter (T7 p/p system). Unfortunately, in this system, target protein expression gradually declines and is often undetectable following 3 to 5 subcultures. Although a number of studies have attempted to stabilize the expression levels of the T7 p/p system, none has resolved the problem adequately and thus precludes the use of this system for the production of recombinant proteins on a large scale.
- 1 January 2012
- Published by Springer Nature in Microbial Cell Factories
- Vol. 11 (1) , 109
Open AccessA novel system for stable, high-level expression from the T7 promoter
The most widespread, efficient prokaryotic protein-producing system is one where the T7 phage polymerase recognizes the T7 phage promoter (T7 p/p system). Unfortunately, in this system, target protein expression gradually declines and is often undetectable following 3 to 5 subcultures. Although a number of studies have attempted to stabilize the expression levels of the T7 p/p system, none has resolved the problem adequately and thus precludes the use of this system for the production of recombinant proteins on a large scale.